Towa Pharmaceutical Co., Ltd.
Towa Pharmaceutical Announces Share Issue to Third Parties and Capital Policy | May 2026
Towa Pharmaceutical plans to issue up to 20 billion yen of preferred shares through third-party allotment on May 21, 2026, to fund capital expenditures and collaborations. They will also execute amendments to the articles of incorporation and reduce capital to strengthen their financial base.
Key Figures
- Funding Amount: Up to 20 billion yen
- Decrease in Capital: 50 billion yen
- Number of Issued Shares (First A-type Preferred Shares): 10,000 shares
AI要約
Overview of Capital Policy
Towa Pharmaceutical decided to issue up to 20 billion yen of preferred shares through a board resolution on May 21, 2026. They will also reduce capital by 5 billion yen and amend the articles of incorporation to allocate funds for capital expenditures and collaboration projects. This aims to support business growth and strengthen the financial foundation.
Future Outlook and Shareholder Impact
The funds raised will be used to expand manufacturing lines and invest in collaborations, contributing to business expansion and the development of a stable supply system. The capital reduction will not affect net assets, and there is likely to be no direct change in shareholders' voting rights or ownership ratios.
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
